Emily Kaiser Maharjan

Mark Breazzano, MD, discusses his views on the future of telehealth for ophthalmologists and retina specialists.

Mark Breazzano, MD, discusses his research into the decrease in urgent and emergent procedures in ophthalmology, how he's handling it in his practice, and how to make patients more comfortable coming in to receive care.

A poll for retina specialists across the globe as the EURETINA 2021 virtual meeting approaches.

Dr. Mark Breazzano discusses the impact of COVID-19 on his practice and how patients are reacting.

Mark Breazzano, MD, discusses the future of retina specialists' practice within context of the ongoing pandemic.

Dr. Mark Breazzano discusses pandemic-related patient hesitancy and how retina specialists can help.

Outlook Therapeutics completes Phase 3 NORSE TWO safety and efficacy trial for ONS-5010, an investigational ophthalmic formulation of bevacizumab for treatment of wet AMD.

Mark Breazzano, MD, discusses the future of telehealth for retina specialists.

The U.S. FDA granted orphan drug designation to ADX-2191, methotrexate for intravitreal injection, as treatment for retinitis pigmentosa.

If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.

The American Society of Cataract and Refractive Surgery hosted its 2021 ASCRS and ASOA Annual Meeting July 23-27 in Las Vegas, Nevada.

Mark Breazzano, MD, discusses the effects of the COVID-19 pandemic on daily practice for retina specialists.

A poll for ophthalmologists and retina specialists to celebrate UV Safety Month. This poll will close July 28, 2021.

As the Fourth of July approaches, ophthalmologists warn patients to exercise caution with fireworks.

A survey of fireworks-related injuries for ophthalmologists and retina specialists.